Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


Evogene embarks on US IPO

The Israeli biotechnology company, Evogene (Rehovot), aims to sell 5 million shares at $14.75/share through its initial public offering (IPO) on the US New York Stock Exchange. Monsanto has agreed to purchase 813,560 shares at the IPO price, amounting to some $12 million. As of June 30th, Monsanto held an 8.7% stake in Evogene (Agrow No 673, p 2). Shares were due to begin trading on November 21st and the IPO is expected to close on November 26th. Evogene intends to use about half of the proceeds from the IPO on its seed trait research, with the remainder being targeted at "ag chemicals" and biofuels (Agrow ibid).


What to read next




Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts